Chun-Song Yang1,2, Yun-Zhu Lin3,4, Qin Guo2,5, Li-Li He6. 1. Department of Pharmacy, Evidence-Based Pharmacy Centre, West China Second Hospital, Sichuan University, Chengdu, 610041, China. 2. West China Second Hospital, Key Laboratory of Birth Defects and Related Diseases of Women and Children, Sichuan University, Chengdu, 610041, China. 3. Department of Pharmacy, Evidence-Based Pharmacy Centre, West China Second Hospital, Sichuan University, Chengdu, 610041, China. linyunzhu99@163.com. 4. West China Second Hospital, Key Laboratory of Birth Defects and Related Diseases of Women and Children, Sichuan University, Chengdu, 610041, China. linyunzhu99@163.com. 5. Department of Pediatrics, West China Second Hospital, Sichuan University, Chengdu, 610041, China. 6. College of Chemistry and Environment Protection, Southwest University for Nationalities, Chengdu, 610041, China.
Abstract
OBJECTIVES: To evaluate the efficacy and safety of Chinese herbal medicine Xingnaojing Injection () for newborns with hypoxic ischemic encephalopathy (HIE). METHODS: Literatures were identified by searching the PubMed, EMBASE, Cochrane Library, Cochrane Central, and four Chinese literature databases from the establishment of database to October in 2013. Relevant reference lists were also screened. Two reviewers independently evaluated the methodological quality of included studies. We also conducted the meta-analysis. RESULTS: Thirteen trials involving 1,169 patients were included. There was no trial reported death or disability at the end of follow-up period. Meta-analysis of 4 trials (n=371) showed that there was no significant difference in the reduction of mortality [risk ratios (RR)=0.48, 95% confidence intervals (CI, 0.21, 1.13), P=0.09] between the Xingnaojing and control groups. Meta-analysis of 5 trials (n=359) showed that there was significant difference in reducing the major neurodevelopmental disability [RR=0.36, 95% CI (0.19, 0.66), P=0.001]. Meta-analysis of 6 trials (n=447) showed that there was significant difference in the author self-defined symptom improvement [RR=1.25, 95% CI (1.14, 1.37), P<0.01]. No fatal side-effects were reported. CONCLUSION: Based on the limited evidence, the routine use of Xingnaojing Injection for treatment of HIE in newborns is not recommended. Further well-conducted trials are justified.
OBJECTIVES: To evaluate the efficacy and safety of Chinese herbal medicine Xingnaojing Injection () for newborns with hypoxic ischemicencephalopathy (HIE). METHODS: Literatures were identified by searching the PubMed, EMBASE, Cochrane Library, Cochrane Central, and four Chinese literature databases from the establishment of database to October in 2013. Relevant reference lists were also screened. Two reviewers independently evaluated the methodological quality of included studies. We also conducted the meta-analysis. RESULTS: Thirteen trials involving 1,169 patients were included. There was no trial reported death or disability at the end of follow-up period. Meta-analysis of 4 trials (n=371) showed that there was no significant difference in the reduction of mortality [risk ratios (RR)=0.48, 95% confidence intervals (CI, 0.21, 1.13), P=0.09] between the Xingnaojing and control groups. Meta-analysis of 5 trials (n=359) showed that there was significant difference in reducing the major neurodevelopmental disability [RR=0.36, 95% CI (0.19, 0.66), P=0.001]. Meta-analysis of 6 trials (n=447) showed that there was significant difference in the author self-defined symptom improvement [RR=1.25, 95% CI (1.14, 1.37), P<0.01]. No fatal side-effects were reported. CONCLUSION: Based on the limited evidence, the routine use of Xingnaojing Injection for treatment of HIE in newborns is not recommended. Further well-conducted trials are justified.
Entities:
Keywords:
Chinese herbal medicine; hypoxic ischemic encephalopathy; newborns; systematic review
Authors: Seetha Shankaran; Athina Pappas; Scott A McDonald; Betty R Vohr; Susan R Hintz; Kimberly Yolton; Kathryn E Gustafson; Theresa M Leach; Charles Green; Rebecca Bara; Carolyn M Petrie Huitema; Richard A Ehrenkranz; Jon E Tyson; Abhik Das; Jane Hammond; Myriam Peralta-Carcelen; Patricia W Evans; Roy J Heyne; Deanne E Wilson-Costello; Yvonne E Vaucher; Charles R Bauer; Anna M Dusick; Ira Adams-Chapman; Ricki F Goldstein; Ronnie Guillet; Lu-Ann Papile; Rosemary D Higgins Journal: N Engl J Med Date: 2012-05-31 Impact factor: 91.245
Authors: Eric Manheimer; Susan Wieland; Elizabeth Kimbrough; Ker Cheng; Brian M Berman Journal: J Altern Complement Med Date: 2009-09 Impact factor: 2.579
Authors: Charlie C L Xue; Anthony L Zhang; Kenneth M Greenwood; Vivian Lin; David F Story Journal: J Altern Complement Med Date: 2010-03 Impact factor: 2.579